Global Health

IDSA and HIVMA Global Impact: 2018 and Beyond

IDSA and HIVMA Letter on NDAA (PDF)

IDSA Letter to New WHO Director General (PDF)

IDSA Letter to New USAID Administrator

IDSA Letter on Moscow TB Declaration (PDF)

Letter to Secretary of State on Global HIV Funding

GAPP Politico Ad

Joint Letter on FDA Priority Review Voucher Program (PDF)

Medical Societies Write to HHS Secretary on Fogarty (PDF)

Physicians Ask President Trump for Robust Global ID Response (PDF)

Joint Letter to Office of US Global AIDS Coordinator and Health Diplomacy on Need for IPT Data (PDF)

Letter to Senate Leaders on Military Medical Research (PDF)

Report on CROI 2017 (PDF)

Launched in 1993 as a forum for basic scientists and clinical investigators from around the world to share and discuss laboratory science, clinical trials and evolving practice confronting HIV and its associated impacts, the Conference on Retroviruses and Opportunistic Infections has provided the setting for presentations of landmark research heralding advances against the pandemic.

Report on 47th Union World Conference on Lung Health (PDF)

The resistance that enabled tuberculosis to resurge from a sickness considered all but conquered in the last century, to one that in this century kills more people than any other infectious disease on earth, goes beyond the mutations of the bacteria that survive initial treatment.

Fogarty International Center (PDF)

The Fogarty International Center, founded in 1968 and part of the National Institutes of Health, connects American scientists and health-care professionals with their global health peers to support basic, clinical, and applied research along with training programs in low-and middle-income countries.

Updated Zika White Paper 2017 (PDF)

Before the 2015 arrival of Zika virus in the Western Hemisphere, a mosquito bite had never before been linked to a devastating birth defect.

New White Paper on Tuberculosis (PDF)

About a third of the world’s population is infected with the bacterium that causes active, infectious tuberculosis disease. While 90 percent of infected people will not progress to disease, people with compromised immune systems, including from HIV, face much greater risks of illness.

New White Paper on Global Antimicrobial Resistance (PDF)

The development of medicines that control bacteria, viruses, parasites and fungi ushered in the era of modern medicine over the last century.

Report on 2016 International AIDS Conference (PDF)

The 2016 International AIDS Conference returned to the South African city and to a country that is home to the largest HIV treatment program in the world, while more than 17 million people globally are accessing antiretroviral treatment.

New White Paper on HIV (PDF)

Since surfacing in 1981, the global HIV pandemic is estimated to have infected 78 million people, killed 39 million, left more than 17 million orphans, reversed an upward trend in life expectancy around the world, and, in the process, turned the clock back on health systems, education and economic development in some of the poorest countries in the world. Today, more than 37 million people worldwide are infected with HIV.

New White Paper on Zika (PDF)

Before the 2015 arrival of Zika virus in the Western Hemisphere, a mosquito bite had never before been linked to a devastating birth defect.

Redeployment: Opportunities to Control HIV and TB in Tanzania (PDF)

The Infectious Diseases Society of America Education and Research Foundation Center for Global Health Policy hosted five Congressional staff delegates on a visit to Tanzania in October 2014 to witness the impacts of United States investments in responses to the HIV and tuberculosis epidemics there, and to discover obstacles to prevention and treatment of those diseases in the country.

Red Ribbon or White Flag? The Future of the US Global AIDS Response (PDF)

This report from the ONE campaign details the impacts of the White House’s proposed budget cuts to US global HIV funding and subsequent PEPFAR strategy on the global AIDS response.

The Ascent Begins: Tuberculosis Research Funding Trends, 2005-2016

The latest report from the Treatment Action Group on funding trends for global tuberculosis research and development shows there has been increases in spending on TB research, but overall funding remains inadequate for achieving global goals to eliminate the epidemic by 2030.

Healthier World, Safer America: A US Government Roadmap for International Action to Prevent the Next Pandemic (PDF)

This report from PATH analyzes the importance of developing a robust pipeline of new drugs, diagnostics, vaccines and other technologies for diseases likely to become pandemics, and outlines recommendations for action from the US government to prevent the next pandemic.